FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971181330> ?p ?o ?g. }

• W1971181330 endingPage "96" @default.
• W1971181330 startingPage "85" @default.
• W1971181330 abstract "The purpose of this study is to provisionally classify, based on the Biopharmaceutics Classification System (BCS), drugs in immediate-release dosage forms that appear on the World Health Organization (WHO) Essential Drug List. The classification in this report is based on the aqueous solubility of the drugs reported in commonly available reference literature and a correlation of human intestinal membrane permeability for a set of 29 reference drugs with their calculated partition coefficients. The WHO Essential Drug List consists of a total of 325 medicines and 260 drugs, of which 123 are oral drugs in immediate-release (IR) products. Drugs with dose numbers less than or equal to unity [Do = (maximum dose strength/250 mL)/solubility < or = 1] are defined as high-solubility drugs. Drug solubility for the uncharged, lowest-solubility form reported in the Merck Index or USP was used. Of the 123 WHO oral drugs in immediate-release dosage forms, 67% (82) were determined to be high-solubility drugs. The classification of permeability is based on correlations of human intestinal permeability of 29 reference drugs with the estimated log P or CLogP lipophilicity values. Metoprolol was chosen as the reference compound for permeability and log P or CLogP. Log P and CLogP were linearly correlated (r2 = 0.78) for 104 drugs. A total of 53 (43.1%) and 62 (50.4%) drugs on the WHO list exhibited log P and CLogP estimates, respectively, that were greater than or equal to the corresponding metoprolol value and are classified as high-permeability drugs. The percentages of the drugs in immediate-release dosage forms that were classified as BCS Class 1, Class 2, Class 3, and Class 4 drugs using dose number and log Pwere as follows: 23.6% in Class 1, 17.1% in Class 2, 31.7% in Class 3, and 10.6% in Class 4. The remaining 17.1% of the drugs could not be classified because of the inability to calculate log P values because of missing fragments. The corresponding percentages in the various BCS classes with dose number and CLogP criteria were similar: 28.5% in Class 1, 19.5% in Class 2, 35.0% in Class 3, and 9.8% in Class 4. The remaining 7.3% of the drugs could not be classified since CLogP could not be calculated. These results suggest that a satisfactory bioequivalence (BE) test for more than 55% of the high-solubility Class 1 and Class 3 drug products on the WHO Essential Drug List may be based on an in vitro dissolution test. The use of more easily implemented, routinely monitored, and reliable in vitro dissolution tests can ensure the clinical performance of drug products that appear on the WHO Essential Medicines List." @default.
• W1971181330 created "2016-06-24" @default.
• W1971181330 creator A5014715117 @default.
• W1971181330 creator A5018506403 @default.
• W1971181330 creator A5020138765 @default.
• W1971181330 creator A5031225531 @default.
• W1971181330 creator A5033052131 @default.
• W1971181330 creator A5041843469 @default.
• W1971181330 creator A5075309403 @default.
• W1971181330 creator A5085453188 @default.
• W1971181330 creator A5087021093 @default.
• W1971181330 creator A5088832801 @default.
• W1971181330 creator A5089505115 @default.
• W1971181330 date "2003-12-17" @default.
• W1971181330 modified "2023-09-30" @default.
• W1971181330 title "Molecular Properties of WHO Essential Drugs and Provisional Biopharmaceutical Classification" @default.
• W1971181330 cites W1499768710 @default.
• W1971181330 cites W1522767714 @default.
• W1971181330 cites W1568759573 @default.
• W1971181330 cites W2000219706 @default.
• W1971181330 cites W2024362305 @default.
• W1971181330 cites W2048312836 @default.
• W1971181330 cites W2060917067 @default.
• W1971181330 cites W2062338388 @default.
• W1971181330 cites W2089118929 @default.
• W1971181330 cites W2144335239 @default.
• W1971181330 doi "https://doi.org/10.1021/mp034006h" @default.
• W1971181330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15832504" @default.
• W1971181330 hasPublicationYear "2003" @default.
• W1971181330 type Work @default.
• W1971181330 sameAs 1971181330 @default.
• W1971181330 citedByCount "753" @default.
• W1971181330 countsByYear W19711813302012 @default.
• W1971181330 countsByYear W19711813302013 @default.
• W1971181330 countsByYear W19711813302014 @default.
• W1971181330 countsByYear W19711813302015 @default.
• W1971181330 countsByYear W19711813302016 @default.
• W1971181330 countsByYear W19711813302017 @default.
• W1971181330 countsByYear W19711813302018 @default.
• W1971181330 countsByYear W19711813302019 @default.
• W1971181330 countsByYear W19711813302020 @default.
• W1971181330 countsByYear W19711813302021 @default.
• W1971181330 countsByYear W19711813302022 @default.
• W1971181330 countsByYear W19711813302023 @default.
• W1971181330 crossrefType "journal-article" @default.
• W1971181330 hasAuthorship W1971181330A5014715117 @default.
• W1971181330 hasAuthorship W1971181330A5018506403 @default.
• W1971181330 hasAuthorship W1971181330A5020138765 @default.
• W1971181330 hasAuthorship W1971181330A5031225531 @default.
• W1971181330 hasAuthorship W1971181330A5033052131 @default.
• W1971181330 hasAuthorship W1971181330A5041843469 @default.
• W1971181330 hasAuthorship W1971181330A5075309403 @default.
• W1971181330 hasAuthorship W1971181330A5085453188 @default.
• W1971181330 hasAuthorship W1971181330A5087021093 @default.
• W1971181330 hasAuthorship W1971181330A5088832801 @default.
• W1971181330 hasAuthorship W1971181330A5089505115 @default.
• W1971181330 hasConcept C116073593 @default.
• W1971181330 hasConcept C155574463 @default.
• W1971181330 hasConcept C160492267 @default.
• W1971181330 hasConcept C178790620 @default.
• W1971181330 hasConcept C185592680 @default.
• W1971181330 hasConcept C192552737 @default.
• W1971181330 hasConcept C201399114 @default.
• W1971181330 hasConcept C202751555 @default.
• W1971181330 hasConcept C203014093 @default.
• W1971181330 hasConcept C2780035454 @default.
• W1971181330 hasConcept C2781047461 @default.
• W1971181330 hasConcept C2781071285 @default.
• W1971181330 hasConcept C2781430271 @default.
• W1971181330 hasConcept C2910701995 @default.
• W1971181330 hasConcept C2992270614 @default.
• W1971181330 hasConcept C41625074 @default.
• W1971181330 hasConcept C43617362 @default.
• W1971181330 hasConcept C54355233 @default.
• W1971181330 hasConcept C55493867 @default.
• W1971181330 hasConcept C71240020 @default.
• W1971181330 hasConcept C71924100 @default.
• W1971181330 hasConcept C77281830 @default.
• W1971181330 hasConcept C86803240 @default.
• W1971181330 hasConcept C98274493 @default.
• W1971181330 hasConceptScore W1971181330C116073593 @default.
• W1971181330 hasConceptScore W1971181330C155574463 @default.
• W1971181330 hasConceptScore W1971181330C160492267 @default.
• W1971181330 hasConceptScore W1971181330C178790620 @default.
• W1971181330 hasConceptScore W1971181330C185592680 @default.
• W1971181330 hasConceptScore W1971181330C192552737 @default.
• W1971181330 hasConceptScore W1971181330C201399114 @default.
• W1971181330 hasConceptScore W1971181330C202751555 @default.
• W1971181330 hasConceptScore W1971181330C203014093 @default.
• W1971181330 hasConceptScore W1971181330C2780035454 @default.
• W1971181330 hasConceptScore W1971181330C2781047461 @default.
• W1971181330 hasConceptScore W1971181330C2781071285 @default.
• W1971181330 hasConceptScore W1971181330C2781430271 @default.
• W1971181330 hasConceptScore W1971181330C2910701995 @default.
• W1971181330 hasConceptScore W1971181330C2992270614 @default.
• W1971181330 hasConceptScore W1971181330C41625074 @default.
• W1971181330 hasConceptScore W1971181330C43617362 @default.
• W1971181330 hasConceptScore W1971181330C54355233 @default.

• next